| Name | Title | Contact Details |
|---|---|---|
Rolf Ramelmeier |
Chief Technology Officer | Profile |
Angela Thedinga |
Chief Technology Officer | Profile |
Neuros Medical, a Cleveland, Ohio based neurostimulation company, is focused on developing proprietary neurostimulation therapies for unmet needs to patients worldwide.
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.
Roswell Biotechnologies is a molecular electronics company transforming DNA sequencing with their latest platform, designed to deliver the disruptive performance required for future biomedical and industrial applications.
Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV), and other SMNH product candidates, including SB 11285, the company`s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of Interferon Genes, or STING, pathway.
Federation Bio is a biotechnology company pioneering a novel approach to create potent, durable and safe cell therapies. The company`s first-in-class platform combines the power of genetic engineering and synthetic consortium design to control systemic immune responses and broad metabolic functions. Federation Bio`s pipeline addresses a range of serious illnesses from metabolic disorders to metastatic cancer. The company`s lead program is in enteric hyperoxaluria, a serious renal condition that affects more than 250,000 Americans and for which there are currently no approved therapies.